Cochrane · systematic review · CD012820
Cannabinoids for the treatment of dementia
Bosnjak Kuharic, D, Markovic, D, Brkovic, T, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison: cannabinoids compared to placebo for the treatment of dementia
Population: diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Changes in global and specific cognitive functions, sMMSE scale ( Comparison: cannabinoids vs placebo | no estimate extracted | 1 study · 39 participants | Very low Downgraded: risk of bias, indirectness |
Overall behavioural and psychological symptoms of dementia, NPI and NPI‐NH total score ( Comparison: cannabinoids vs placebo | no estimate extracted | 3 studies · 111 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Agitated or aggressive behaviours in dementia patients, measured on the Cohen‐Mansfield Agitation Inventory (CMAI) Scale (range 29 to 203, with 29 meaning no symptoms, and higher number of points indicating more severe symptoms)Â Comparison: cannabinoids vs placebo | no estimate extracted | 3 studies · 100 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events ‐ nervous system disorders ‐ total nervous system disorders ( Comparison: cannabinoids vs placebo | OR 0.71 [0.23, 2.18] | 1 study · 50 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events ‐ psychiatric disorders ‐ total psychiatric disorders ( Comparison: cannabinoids vs placebo | OR 2.26 [0.57, 9.02] | 1 study · 50 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events ‐ gastrointestinal disorders ‐ total gastrointestinal disorders ( Comparison: cannabinoids vs placebo | OR 2.4 [0.4, 14.49] | 1 study · 50 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events ‐ general ‐ total general adverse events ( Comparison: cannabinoids vs placebo | OR 0.7 [0.11, 4.58] | 1 study · 50 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |